溴隐亭联合美多芭治疗醒状昏迷患者的效果及安全性分析  

Analysis of the Effect and Safety of Bromocriptine and Medopa in the Treatment of Patients with Waking Coma

作　　者：黄剑 陈小宝 张涛 钱锁开 HUANG Jian;CHEN Xiaobao;ZHANG Tao;QIAN Suoka(Jiangxi Jiayou Shuguang Orthopedic Hospital,Nanchang Jiangxi 333000,China)

机构地区：[1]江西嘉佑曙光骨科医院,南昌333000

出　　处：《药品评价》2020年第18期34-35,49,共3页Drug Evaluation

摘　　要：目的:探讨溴隐亭联合美多芭治疗醒状昏迷患者的效果及安全性。方法:选取我院2017年10月—2019年12月期间接收的80例昏迷患者,根据随机数字表法分为对照组和观察组各40例。对照组采用溴隐亭治疗,观察组在对照组基础上联合美多芭治疗,比较两组治疗前后各个周期的疗效、神经功能及不良反应。结果:观察组治疗3个周期、6个周期、9个周期的PVS评分均高于对照组,EDSS评分均低于对照组,不良反应发生率低于对照组,差异均有统计学意义(P<0.05)。结论:溴隐亭联合美多芭可显著改善昏迷患者的意识状态及神经功能,降低不良反应发生率,值得临床推广。Objective:To investigate the efficacy and safety of bromocriptine and Medopa in the treatment of patients with coma.Methods:80 comatose patients in our hospital from October 2017 to December 2019 were selected and randomly divided into control group and observation group with 40 cases in each group.The control group was treated with bromocriptine,and the observation group was treated with Medopa on the basis of the control group.The efficacy,neurological function and adverse reactions of the two groups before and after treatment were compared.Results:The PVS scores of 3,6 and 9 cycles in the observation group were higher than those in the control group,the EDSS scores were lower than those in the control group,and the incidence of adverse reactions was lower than that of the control group(P<0.05).Conclusion:Bromocriptine combined with Medopa can significantly improve the state of consciousness and neurological function of coma patients,reduce the incidence of adverse reactions,which is worthy of clinical promotion.

关 键 词：醒状昏迷 溴隐亭 美多芭 神经功能 不良反应 

分 类 号：R969.4[医药卫生—药理学]